Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2023-08-24 00:00:00 ET · period of report 2023-08-23 · accession 0001104659-23-095017 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2023-08-24 | 2022-08-23 | APRE | Duey Marc | Dir | C - Cnv Deriv | $0.00 | +11.6K | 602 | New | $0 |
| D | 2023-08-24 | 2023-08-23 | APRE | Duey Marc | Dir | A - Grant | $0.00 | +500 | 208.9K | +0.2% | $0 |
| D | 2023-08-24 | 2022-08-23 | APRE | Duey Marc | Dir | C - Cnv Deriv | $0.00 | +4.01M | 4.17M | +2,539% | $0 |
| D | 2023-08-24 | 2022-08-23 | APRE | Duey Marc | Dir | C - Cnv Deriv | $0.00 | -401.0K | 0 | -100% | $0 |
| D | 2023-08-24 | 2023-08-23 | APRE | Duey Marc | Dir | A - Grant | $0.00 | +2,000 | 2,000 | New | $0 |
| DI | 2023-08-24 | 2022-08-23 | APRE | Duey Marc | Dir | C - Cnv Deriv | $0.00 | -1,161 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-23 | C | A | 11,610 | $0.00 | 602 | I | — | — | (F2) Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023 |
| 2 | Common | Common Stock | 2023-08-23 | A | A | 500 | $0.00 | 208,878 | D | — | — | (F1) These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. (F2) Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023 |
| 3 | Common | Common Stock | 2022-08-23 | C | A | 4,009,690 | $0.00 | 4,167,589 | D By Spouse | — | — | (F3) The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. |
| 4 | Derivative | Series A Non-Voting Convertible Preferred Stock | 2022-08-23 | C | D | 400,969 | $0.00 | 0 | D By Spouse | $0.00 · — to — | 4,009,690 Common Stock | (F3) The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. (F4) Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock ("Common Stock") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date. |
| 5 | Derivative | Stock Options (Right to Buy) | 2023-08-23 | A | A | 2,000 | $0.00 | 2,000 | D | $3.65 · — to 2033-08-23 | 2,000 Common Stock | (F5) The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
| 6 | Derivative | Series A Non-Voting Convertible Preferred Stock | 2022-08-23 | C | D | 1,161 | $0.00 | 0 | I | $0.00 · — to — | 11,610 Common Stock | (F4) Following stockholder approval at the Issuer's annual stockholder's meeting, each share of Series A Non-Voting Convertible Preferred Stock is convertible into 10 shares of the Issuer's common stock ("Common Stock") at any time at the option of the holder thereof, subject to certain limitations, including that a holder of Series A Non-Voting Convertible Preferred Stock is prohibited from converting shares of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Series A Non-Voting Convertible Preferred Stock has no expiration date. |